MedTrace Logo

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-09-18

No results posted yet for this study

Summary

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Conditions

  • CLL/SLL

Interventions

DRUG

lisaftoclax +BTK inhibitor

lisaftolax + BTK inhibitor

DRUG

BTK inhibitor

BTK inhibitor

Sponsors & Collaborators

  • Ascentage Pharma Group Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-20
Primary Completion
2025-10-20
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06104566 on ClinicalTrials.gov